Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the Amer...
April 24 2017 - 2:18PM
Oral presentation of first achievement of in vivo
retinal gene editing in non-human primates
Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing
company, today announced that six scientific abstracts have been
accepted for presentation at the 20th Annual Meeting of the
American Society of Gene & Cell Therapy (ASGCT). The meeting
will take place May 10-13 in Washington, D.C. The Company is
presenting data on its pipeline and platform technologies to
support ongoing development programs.
Key Editas Medicine presentations at ASGCT will include data
demonstrating:
- First report of results from in vivo gene editing of inherited
retinal disease genes in non-human primates;
- CRISPR/Cas9-mediated editing and engraftment of hematopoietic
stem cells preclinically for the treatment of
β-hemoglobinopathies;
- Self-inactivating Cas9: A proprietary approach for controlling
exposure while maintaining efficacy in virally-delivered Cas9
applications; and
- UDiTaS™: A proprietary genome editing analytical method to
comprehensively characterize multiple forms of editing, including
on- and off-target edits, large deletions, and translocations.
In addition, Editas scientists will be chairing sessions on
cardiovascular and pulmonary gene and cell therapies, on AAV vector
systems, and a scientific symposium on getting cures to
patients.
“Editas Medicine is at the forefront of the rapidly-advancing
science that is unlocking the potential of CRISPR for patients,”
said Katrine Bosley, President and Chief Executive Officer, Editas
Medicine. “These data at ASGCT showcase advances towards our goal
of making medicines for patients suffering from genetically-defined
diseases and, potentially, for more common genetically-treatable
diseases as well.”
The complete list of Editas Medicine presentations is
below. Abstracts can be accessed on the ASGCT website at
www.abstractsonline.com/pp8/#!/4399.
Oral Presentations:Amelioration of Alpha-1
Antitrypsin Deficiency Diseases with Genome Editing in Transgenic
MiceDate/Time: May 10, 11:00-11:15
a.m.Location: Lincoln 5,6
Session: Genome Editing and Integration Analysis
in Metabolic and Endocrine Disorders
CRISPR/Cas9-mediated Editing of Hematopoietic Stem Cells for the
Treatment of β-HemoglobinopathiesDate/Time: May
11, 9:10-9:45 a.m.Location: Lincoln
2,3,4Session: Therapeutic Editing of the Human
Genome and Epigenome
Efficient In Vivo Gene Editing of Inherited Retinal Disease
Genes in Mice and Non-Human PrimatesDate/Time: May
13, 11:00-11:15 a.m.Location: Thurgood Marshall
NorthSession: Preclinical Progress Towards
Therapies for Neurosensory Disorders
Poster Presentations:Characterization of
Targeted Integration with Viral and Non-Viral DNA
DonorsDate/Time: May 11, 5:15-7:15
p.m.Location: Exhibit Hall A & B
SouthSession: Gene Targeting and Gene Correction
II
Self-inactivating Cas9: A method for Reducing Exposure While
Maintaining Efficacy in Virally-delivered Cas9
ApplicationsDate/Time: May 11, 5:15-7:15
p.m.Location: Exhibit Hall A & B
SouthSession: Gene Targeting and Gene Correction
II
UDiTaS™: A Streamlined Genome Editing Detection Method for On-
and Off-target Edits, Large Deletions, and
TranslocationsDate/Time: May 12, 5:45-7:45
p.m.Location: Exhibit Hall A & B
SouthSession: Gene Targeting and Gene Correction
III
About Editas MedicineEditas Medicine is a
leading genome editing company dedicated to treating patients with
genetically-defined diseases by correcting their disease-causing
genes. The Company was founded by world leaders in genome editing,
and its mission is to translate the promise of genome editing
science into a broad class of transformative genomic medicines to
benefit the greatest number of patients.
Forward-Looking Statements
This press release contains forward-looking statements and
information within the meaning of The Private Securities Litigation
Reform Act of 1995. The words “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “target,” “should,” “would,”
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. The Company may not actually achieve the
plans, intentions, or expectations disclosed in these
forward-looking statements, and you should not place undue reliance
on these forward-looking statements. Actual results or events
could differ materially from the plans, intentions and expectations
disclosed in these forward-looking statements as a result of
various factors, including: uncertainties inherent in the
initiation and completion of preclinical studies and clinical
trials and clinical development of the Company’s product
candidates; availability and timing of results from preclinical
studies and clinical trials; whether interim results from a
clinical trial will be predictive of the final results of the trial
or the results of future trials; expectations for regulatory
approvals to conduct trials or to market products and availability
of funding sufficient for the Company’s foreseeable and
unforeseeable operating expenses and capital expenditure
requirements. These and other risks are described in greater
detail under the caption “Risk Factors” included in the Company’s
most recent Annual Report on Form 10-K, which is on file with the
Securities and Exchange Commission, and in other filings that the
Company may make with the Securities and Exchange Commission in the
future. Any forward-looking statements contained in this
press release speak only as of the date hereof, and the Company
expressly disclaims any obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts
Media:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
Investors:
Mark Mullikin
(617) 401-9083
mark.mullikin@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Sep 2023 to Sep 2024